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Summary
Romiplostim can improve platelet counts in about 50% of patients with
low- or intermediate 1-risk (lower risk) myelodysplastic syndromes (MDS)
and thrombocytopenia, but its long-term toxicity and efficacy are not
known. This open-label extension study evaluated the long-term safety and
efficacy of romiplostim in 60 patients with lower risk MDS and platelet
counts ≤50 9 109/l. The primary endpoint was adverse event (AE) inci-
dence. Secondary endpoints were efficacy parameters, including bleeding
events and platelet response. Median (range) treatment time in the exten-
sion study and the median observation times thereafter were 25 (2–181)
and 57 (11–209) weeks, respectively. Treatment-related AEs and serious
AEs were reported in 14/60 (23%) and 4/60 (7%) patients, respectively.
Progression to acute myeloid leukaemia (AML) occurred in two patients
after 44 and 46 weeks. Patients (n = 34, 57%) with a platelet response were
further evaluated for length of response. Median (range) response duration
was 33 (7–174) weeks; 28/34 (82%) patients had a continuous response.
Five of 34 patients (15%) had grade ≥3 bleeding events; three when the
platelet count was >50 9 109/l. There were no new safety concerns and the
rate of progression to AML was low; response to romiplostim was main-
tained for most patients.
Keywords: romiplostim, myelodysplastic syndromes, platelets, thrombo-
cytopenia, thrombopoietin receptor agonist.
Myelodysplastic syndromes (MDS) are haematological malig-
nancies characterised by ineffective clonal haematopoiesis,
cytopenia and, for some patients, progression to acute mye-
loid leukaemia (AML) (Vardiman et al, 2009; Neukirchen
et al, 2011). Thrombocytopenia is found in 40–65% of MDS
patients and is associated with reduced survival and increased
bleeding risk (Kantarjian et al, 2007, 2008). The incidence of
thrombocytopenia in patients with MDS increases with
increasing International Prognostic Scoring System (IPSS)
risk group (Kantarjian et al, 2007). Patients with MDS who
have thrombocytopenia are at risk for a range of bleeding
events, from minor bleeding that does not affect survival but
does impact quality of life (i.e., petechiae, gingival bleeding
and retinal haemorrhages), to more serious and potentially
life-threatening bleeding, such as intracranial or pulmonary
haemorrhage (Hofmann & Koeffler, 2005).
Therapeutic options to treat thrombocytopenia in MDS
patients with lower risk of death or progression to AML are
limited (National Comprehensive Cancer Network, 2015). Most
patients do not have serious enough disease to justify allogeneic
haematopoietic cell transplantation (National Comprehensive
Cancer Network, 2015). Other treatments for thrombocytope-
nia in MDS include anabolic steroids, immunosuppressive ther-
apy and hypomethylating agents (National Comprehensive
Cancer Network, 2015; Gangat et al, 2016), although these have
limited efficacy. Platelet transfusions therefore remain the stan-
dard approach to thrombocytopenia associated with MDS
(National Comprehensive Cancer Network, 2015), and 6–33%
of patients with MDS are platelet transfusion-dependent
(Sekeres et al, 2008).
Romiplostim (Nplate; Amgen Inc., Thousand Oaks, CA) is
a recombinant peptibody that targets the thrombopoietin
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(TPO) receptor to increase platelet production and is
approved for use in adults with chronic immune thrombocy-
topenia (http://www.ema.europa.eu/docs/en_GB/document_
library/EPAR_-_Product_Information/human/000942/WC500
039537.pdf; https://www.accessdata.fda.gov/drugsatfda_docs/
label/2016/125268s155s156lbl.pdf). Treatment with romi-
plostim improves platelet counts in 40–50% of lower-risk
MDS patients, decreases bleeding, and reduces the need for
platelet transfusions (Kantarjian et al, 2010; Giagounidis et al,
2014), but its long-term safety (in terms of increased risk of
progression to AML, bone marrow fibrosis, and thromboem-
bolic events) and long-term efficacy are not known.
In this open-label extension study, we examined the long-
term safety and efficacy of romiplostim for the treatment of
thrombocytopenia in patients with MDS who completed par-
ent studies in which they received monotherapy with romi-
plostim or placebo. This trial was prematurely discontinued
because of a suspected safety concern for AML progression,
and because transient increases in blast cell counts could lead
to mistaken diagnosis and treatment for AML; therefore, the
rates of progression to AML and increases in blast cells were
of particular interest.
Methods
Patients
Patients included in the present analysis had completed one
of two parent trials that evaluated romiplostim monotherapy
in a romiplostim versus placebo (Giagounidis et al, 2014) or
open-label romiplostim study (Kantarjian et al, 2010; Sekeres
et al, 2011) for thrombocytopenia in adults with IPSS low-
or intermediate 1-risk MDS at diagnosis (Fig 1; methods and
outcomes of these trials have been published (Giagounidis
et al, 2014; Kantarjian et al, 2010; Sekeres et al, 2011).
Patients were eligible to enrol in the extension trial provided
they met the eligibility criteria, which included a platelet
count ≤50 9 109/l for at least 4 weeks since the last dose of
romiplostim in the parent study and Eastern Cooperative
Oncology Group performance status of 0–2. Key exclusion
criteria were marrow blast count ≥10%, history of progres-
sion to AML, haematopoietic stem cell transplantation or
thrombosis. The study was approved by the independent
ethics committee or institutional review board for each site;
all patients provided written informed consent.
Study design and treatment
This open-label extension study was conducted at 14 centres in
the United States, Europe, Canada and Australia (first patient
enrolled on July 17, 2007). Eligible patients received subcuta-
neous romiplostim at the same dose as in their parent study or
were transitioned to the romiplostim regimen closest to the
parent study: i.e., weekly or biweekly 250, 500, 750, 1000 or
1500 lg). Dosing was adjusted if a platelet response was not
achieved or if platelet counts were >450 9 109/l (Table SI)
(Cheson et al, 2006). Treatment continued until either trans-
formation to AML, toxicity, withdrawal of consent, adminis-
trative decision or no platelet response after 4 weeks at the
maximum romiplostim dose of 1000 lg (patients with a previ-
ous dose of 1500 lg in their parent study were permitted to
continue to receive this dose amount); no additional MDS
therapy was permitted. Concomitant medications or treat-
ments necessary to provide adequate supportive care, includ-
ing platelet transfusions, were permitted. Romiplostim
administration in the extension study was ended prematurely
on 25 May 2011, because of suspected concerns from the Data
Monitoring Committee (DMC) about the potential risk of dis-
ease progression to AML, and that transient increases in blast
cell counts might put patients at risk for the mistaken diagno-
sis of and treatment for AML. Patients remained in the study
for long-term follow-up observation until 31 December 2011.
Assessments
The primary endpoint was the incidence of adverse events (AEs)
http://ctep.cancer.gov/protocoldevelopment/electronic_appli
cations/docs/ctcaev3.pdf; Cheson et al, 2006; Vardiman et al,
2002). Key secondary endpoints included incidence of bleeding
events, platelet transfusions and duration of platelet response,
based on International Working Group (IWG) 2006 criteria (Che-
son et al, 2006) (Table SII). Response duration was independently
evaluated by two clinical haematology experts. Responses were
considered sustained if platelet counts remained ≥50 9 109/l
(IWG criteria are established for patients with platelets
<50 9 109/l) or if platelet counts were only transiently decreased
by >50% or to <50 9 109/l because of missed doses (i.e., not con-
sidered relapses per IWG 2006 criteria). Response duration was
examined until patients discontinued romiplostim for any reason.
In this extension study, adverse events, bleeding events,
platelet counts and concomitant medications were assessed at
screening, weekly throughout romiplostim treatment, and at
the end-of-study visit (all patients completed an end-of-study
visit 4 weeks after their last dose of romiplostim). Antibodies
to TPO and romiplostim were assessed at 12-week intervals.
Bone marrow biopsies and aspirates were analysed by a cen-
tral laboratory at screening and at end of study. Following
the end-of-study visit, patients were monitored by telephone
in long-term follow-up every 24 weeks until 31 December
2011 to assess disease status and survival.
Statistical analysis
Patients receiving ≥1 dose of romiplostim in the extension
study were included in the safety analysis set. For the analysis
of the response duration, we included only the 34 patients
who achieved a response per IWG 2006 criteria (Cheson
et al, 2006). Safety data, demographics and baseline charac-
teristics were summarised using descriptive statistics for all
patients (means, medians, and interquartile ranges).
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Results
Patients
In total, 60 patients from the two parent monotherapy tri-
als entered the open-label extension study (Fig 1). This
population included 50 patients who previously received
romiplostim for a median (range) duration of 52 (7–74)
weeks and 10 patients who previously received placebo.
The median (range) study duration for the 60 patients in
their parent studies was 56 (8–75) weeks. Because of vary-
ing times of enrolment in the extension study and the
administrative decision on 25 May 2011 to end the treat-
ment, time spent in the treatment phase of the open-label
extension study varied widely among patients, from 2 to
181 weeks.
Open-label dose-finding
phase 1/2 study
NCT00303472
N = 28
Placebo-controlled
phase 2 study
NCT00614523
N = 32
Enrolled (n = 60)
Analysis sets
Safety analysis set (n = 60)
Efficacy and duration of response (n = 34)
Romiplostim treatment
Received treatment with romiplostim (n = 60)
Safety Analysis Set
Patients who received ≥1 dose of romiplostim (n = 60)
Patients who completed romiplostim treatment phase (n = 0)
Patients who discontinued romiplostim (n = 60)
 Administrative decision (n = 35)
 Adverse event (n = 6)
 Withdrawal of consent (n = 5)
 Disease progression (n = 3)
 Lack of response (n = 3)
 Unknown (n = 3)
 Death (n = 2)
 Requirement for alternative therapy (n = 2)
 Lost to follow-up (n = 1)
Long-term follow-up
Patients who entered long-term follow-up (n = 44)
Patients who completed follow-up (n = 34)
Patients who did not complete follow-up (n = 10)
 Death (n = 5)
 Lost to follow-up (n = 3)
 Consent withdrawn (n = 2)
Response Assessment
Patients with platelet response* (n = 34)
Patients who discontinued romiplostim (n = 34)
 Administrative decision (n = 25)
 Adverse event (n = 5)
 Disease progression to AML (n = 2)
 Requirement for alternative therapy (n = 1)
 Consent withdrawn (n = 1)
Long-term follow-up
Patients who entered long-term follow-up (n = 29)
Patients who completed follow-up (n = 25)
Patients who did not complete follow-up (n = 4)
 Death (n = 2)
 Lost to follow-up (n = 2)
Fig 1. Study design and treatment schema. Patients were enrolled from one of two parent studies: (i) a 52-week, phase 1/2 study of once-weekly
romiplostim 300–1500 lg (Kantarjian et al, 2010; Sekeres et al, 2011); (ii) a 58-week, randomised, phase 2, placebo-controlled study of once-
weekly romiplostim 750 lg.(Giagounidis et al, 2014) *Response per IWG 2006 criteria (Cheson et al, 2006) (Table II). AML, acute myeloid leu-
kaemia.
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Baseline characteristics of patients at the time of entering
the parent studies did not differ between those patients who
did and those who did not enter the extension study (data
not shown). Demographics and disease characteristics at
baseline of the extension study are listed in Table I. The
median (range) age was 71 (32–84) years. The mean (stan-
dard deviation, SD) time from MDS diagnosis to entering
the open-label extension study was 172 (192) weeks (median
104 weeks). Median interquartile range (Q1, Q3) baseline
platelet count was 22 (14, 35) 9 109/l. The median (range)
total observation time in the open-label study treatment
phase and long-term survival follow-up phase was 57 (11–
209) weeks. The treatment phase (romiplostim exposure) in
this extension study lasted a median (range) of 25 (2–
181) weeks, number of doses was 22 (2–178), and the aver-
age weekly dose was 760 (144–1488) lg. The combined
median romiplostim treatment duration was approximately
15 years and for up to 5 years.
All 60 patients discontinued romiplostim in the extension
study. The majority (n = 35, 58%) of patients discontinued
romiplostim treatment because of the administrative decision
of the DMC due to the suspected safety concern of progres-
sion to AML; other reasons for discontinuation are listed in
Fig 1. After the end-of-study visit, 44 patients entered long-
term follow-up, of whom 34 (77%) were followed until the
final study date (31 December 2011). Reasons for discontinu-
ing the long-term follow-up phase before this date were
death (n = 5), loss to follow-up (n = 3) and withdrawal of
consent (n = 2).
Adverse events and serious adverse events
The most commonly reported AEs (those occurring after
initiation of romiplostim in the extension but not necessar-
ily related to treatment) were epistaxis, cough, arthralgia,
haematoma and contusion (Table II).(http://ctep.cancer.gov/
protocoldevelopment/electronic_applications/docs/ctcaev3.pdf)
Fourteen patients (23%) experienced AEs considered treat-
ment-related by the investigator. AEs that led to study
withdrawal occurred in six patients (10%) and included
B-cell lymphoma and pancytopenia (not considered related
to investigational product), and chronic myeloid leukaemia
(BCR-ABL1 confirmed by fluorescence in situ hybridisation),
pulmonary fibrosis, splenomegaly and transient increase of
blast cells in the bone marrow (considered by investigators
to be related to investigational product). Serious AEs,
regardless of their relationship to treatment, occurred in 22
patients (37%), the most common of which were pneumo-
nia (reported in three patients), followed by arthralgia and
urinary tract infection (reported in two patients each).
Treatment-related serious AEs, reported in four patients
(7%), were chronic myeloid leukaemia (leading to study
withdrawal), cerebral ischaemia/intracranial haemorrhage
(leading to withdrawal of romiplostim), pulmonary fibrosis
(leading to study withdrawal) and speech disorder (leading
to change in romiplostim dose) (Table II). Three patients
(5%) died (muscular dystrophy, pulmonary fibrosis and
congestive cardiac failure) during the study period; pul-
monary fibrosis was considered by investigators to be
related to investigational product. Eight patients (13%) had
grade ≥3 bleeding events.
Progression of myelodysplastic syndrome to acute myeloid
leukaemia
Patients who had MDS progression, transient increases in
peripheral blasts, or developed AML are listed in Table SIII.
Two of 60 patients (3%) had progressed to AML during
the treatment phase of the extension; respective romiplostim
exposure was 4 doses in the parent study and 19 doses in
the extension (every other week dosing) in one patient, and
Table I. Baseline demographics and disease characteristics*.
Romiplostim (N = 60)
Male, n (%) 31 (517)
Age, years, median (range) 71 (32–84)
Age ≥65 years, n (%) 46 (767)
Race, n (%)
White 52 (867)
Black 3 (50)
Other 5 (83)
IPSS status,† n (%)
Low 19 (317)
Intermediate-1 39 (650)
Intermediate-2 0
Unknown 2 (33)
WHO classification at screening, n (%)
RCMD 20 (333)
RA 17 (283)
RAEB-1 4 (67)
RAEB-2 1 (17)
RARS 1 (17)
RCMD-RS 3 (50)
MDS-U 14 (233)
Baseline platelet count, n (%)
<20 9 109/l 26 (433)
≥20 9 109/l 34 (567)
ECOG performance status, n (%)
0 38 (633)
1 17 (283)
2 5 (83)
ECOG, Eastern Cooperative Oncology Group; IPSS, International
Prognostic Scoring System; MDS-U, myelodysplastic syndrome
unclassified; RA, refractory anaemia; RAEB, refractory anaemia with
excessive blasts; RARS, refractory anaemia with ringed sideroblasts;
RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS,
refractory cytopenia with multilineage dysplasia with ringed sidero-
blasts; WHO, World Health Organisation.
*Baseline at screening for the extension study.
†At parent study baseline.
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49 doses in the parent study and 47 doses in the extension
(weekly dosing) in the other. Two other patients (3%) had
transient increases in peripheral blast cell counts from 0%
at baseline to <10% at weeks 11 and 25 without disease
progression to AML, respectively, with 13 and 38 weeks of
romiplostim exposure, and 14 and 41 weeks of observation
time. One patient had MDS progression on week 174 after
172 weeks of romiplostim treatment, without progression to
AML through 195 weeks of observation. The annualised
rate of progression to AML in the 60 patients was 2%
(95% confidence interval [CI]; 02%, 7%).
Thromboembolic events and increased bone marrow
reticulin and collagen
Four patients (7%) had thromboembolic events (one
instance each of cerebral ischaemia, myocardial infarction,
thrombophlebitis and thrombosis). Of the 6 patients (10%)
available for assessment, none developed bone marrow retic-
ulin. Similarly, of the 17 patients (28%) available for assess-
ment, no patients developed collagen fibrosis.
Binding and neutralising antibodies
No neutralising antibodies to romiplostim or TPO were
detected (data not shown).
Response duration per international working group 2006
criteria (haematological improvement in platelets)
Fifty patients (83%) had a platelet response, meeting the cri-
teria for either sustained or transient response (Table SII)
during romiplostim treatment. To examine the durability of
responses to romiplostim, we focused our analysis on the 34
of 60 patients (57%) who achieved a platelet response (de-
fined as a response ≥8 weeks per IWG 2006 criteria (Cheson
et al, 2006)) during this open-label extension study (Fig 1).
Of the 34 patients with a response, three had received pla-
cebo and the remaining 31 had received romiplostim for a
median (range) duration of 52 (7–74) weeks in the parent
study. All 34 patients discontinued the treatment phase in
the open-label extension, 25 (74%) owing to administrative
decision, five (15%) owing to AEs, two (6%) to disease pro-
gression to AML, one (3%) for requirement for alternative
therapy, and one (3%) because of consent withdrawal. The
median weekly dose was 750 lg, and median (Q1, Q3) num-
ber of doses was 43 (21, 125). The median (Q1, Q3) time to
first week satisfying response criteria was 2 (1, 3) weeks, and
the median (Q1, Q3) longest response observed was 28 (14,
56) weeks (Table III).(Cheson et al, 2006) The median (Q1,
Q3) duration of romiplostim treatment was 44 (23,
160) weeks. Median (Q1, Q3) percentage of observation time
with a response was 86% (77%, 93%), and the median (Q1,
Q3) dose at first response was 750 (750, 750) lg. Median
platelet counts for patients with a response (Fig 2A) were
consistent over time. At the time of the last dose of romi-
plostim, 32 of the 34 patients were still meeting response cri-
teria; neither of the two patients who were not meeting
haematological improvement with platelet response (HI-P)
criteria at the last platelet count had developed AML or had
progression of their MDS during their long-term follow-up
(68 and 89 weeks of follow-up).
Response duration per modified criteria
Among the responders, some fluctuations in platelet counts
were observed. Transiently decreased platelet counts that
Table II. Overall summary of treatment-emergent AEs* occurring
during the study period.
AEs, n (%) Romiplostim (N = 60)
Total AEs 59 (983)
Grade 3 31 (525)
Grade 4 5 (83)
Grade 5 3 (50)
AEs reported in ≥10% of patients
Epistaxis 20 (333)
Cough 13 (217)
Arthralgia 12 (200)
Haematoma 12 (200)
Contusion 11 (183)
Anaemia 9 (150)
Abdominal pain 9 (150)
Pyrexia 8 (133)
Fatigue 7 (117)
Headache 7 (117)
Back pain 7 (117)
Constipation 6 (100)
Eye haemorrhage 6 (100)
Bronchitis 6 (100)
Nasopharyngitis 6 (100)
Gingival bleeding 6 (100)
Treatment-related AEs 14 (233)
Grade 3 2 (33)
Grade 4 1 (17)
Grade 5 1 (17)
Serious AEs 22 (367)
Treatment-related serious AEs† 4 (67)
Fatal AEs‡ 3 (50)
AEs leading to study withdrawal 6 (100)
AE, adverse event.
*AEs were classified according to the Common Terminology Criteria
for Adverse Events version 3.0 severity grading scale (http://ctep.ca
ncer.gov/protocoldevelopment/electronic_applications/docs/ctcaev3.
pdf).
†Treatment-related serious AEs were cerebral ischaemia (grade 4)/in-
tracranial haemorrhage (grade 2), chronic myeloid leukaemia (grade
3), pulmonary fibrosis (grade 5) and speech disorder (grade 3).
‡Fatal events were congestive heart failure, muscular dystrophy and
pulmonary fibrosis.
P. Fenaux et al
910 ª 2017 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd.
British Journal of Haematology, 2017, 178, 906–913
occurred after a single missed dose, as independently
assessed by two investigators were not considered clinically
meaningful. Overall, 28 of 34 patients (82%) with platelet
response per IWG 2006 criteria had a sustained response
based on our modified criteria during romiplostim treat-
ment. Their median (range) response duration was 33
(7–174) weeks. Nine patients received romiplostim for
<6 months (range, 11–22 weeks); all had a continuous
response during treatment. Ten patients received romi-
plostim for 6–12 months (range, 27–48 weeks), with seven
of 10 patients (70%) having a continuous response during
treatment. Finally, 15 patients received romiplostim for
>12 months (range, 63–181 weeks), with 12 of 15 (80%)
having a continuous response during treatment (range, 61–
174 weeks). The other three patients with >12 months of
treatment had intermittent responses with cumulative
response lengths/total treatment times of 15/181, 35/149,
and 52/177 weeks. Of the 15 patients who received romi-
plostim for more than 12 months, 10 received romiplostim
for >156 weeks (3 years); eight of these patients (53%)
responded continuously. By the end of the treatment pe-
riod, two patients had lost their response: one after 11 out
of 48 total weeks of treatment and the other after 12 out
of 38 total weeks of treatment. Overall, these data indicate
that long-term platelet responses per modified IWG 2006
criteria with romiplostim treatment are possible in patients
with MDS (28 of 34 patients responded as long as they
received treatment), although our analysis was limited by
the premature discontinuation of romiplostim treatment.
Incidence of bleeding events and platelet transfusions
In the patients with responses, the incidence of any bleeding
event during the treatment phase of the extension was
approximately 30% (Fig 2B). Five patients (15%) experi-
enced grade ≥3 bleeding events, and in three of the five
patients, the bleeding events were associated with platelet
counts >50 9 109/l; platelet function and coagulation status/
function were not available in these instances. Twenty of the
34 responding patients (59%) had a mean (SD) of 16 (18)
platelet transfusions during the treatment phase; 14 (41%)
had no transfusions, seven (21%) had one to four transfu-
sions, and 13 (38%) had more than five transfusions.
Discussion
This open-label extension study examined the safety and effi-
cacy of long-term romiplostim monotherapy in patients with
low- to intermediate 1-risk MDS. Of the 60 patients included
in the safety analysis set, 50 had previously received romi-
plostim for a median (range) duration of 52 (7–74) weeks
during their parent studies and then received romiplostim
for a median (range) of 25 (2–181) weeks in this extension
Table III. Response duration in the open-label extension study per
IWG 2006 criteria*.
Romiplostim
n = 34
Time to first week satisfying criteria,† week 21 (11, 30)
Longest continuous response,‡ week 28 (14, 56)
Periods ≥8 consecutive weeks satisfying
response criteria, n
1 (1, 3)
Total number of weeks satisfying response
criteria, n
37 (17, 126)
Percentage of study time meeting response criteria 86 (77, 93)
Dose at first response, lg 750 (750, 750)
Duration of romiplostim treatment, weeks 44 (23, 160)
Not meeting criteria at last platelet count, n (%) 2 (63)
All data are median (interquartile range [Q1, Q3]) unless otherwise
noted.
*Platelet response was based on International Working Group (IWG)
2006 criteria and was defined as (in the absence of platelet transfu-
sion) an absolute increase of ≥30 9 109/l for patients with an initial
platelet count of >20 9 109/l but <100 9 109/l or an increase to
>20 9 109/l and by at least 100% for patients with an initial platelet
count <20 9 109/l for ≥8 weeks.(Cheson et al, 2006).
†Time to the first of 8 weeks to establish response.
‡Defined as continuous response per IWG 2006 criteria.
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Fig 2. (A) Median platelet counts over time and (B) incidence of
bleeding events among patients with platelet response in the open-
label extension exposed to romiplostim during the time interval. Q1,
Q3 = interquartile range.
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study (combined median romiplostim treatment duration of
approximately 15 years and for up to 5 years). The safety
profile observed in this study is consistent with previous
studies. As in previous trials, few patients discontinued
because of AEs, and no patients developed neutralising anti-
bodies to romiplostim or TPO (Kantarjian et al, 2010;
Giagounidis et al, 2014). Three patients died during the
study period; one was considered as possibly related to treat-
ment. Patients achieved durable responses with only two
relapses at the last available platelet count. Most patients
(82%) with responses per IWG 2006 criteria experienced
continuous response with romiplostim treatment as judged
by the clinical experts. Although the IWG 2006 criteria pro-
vided an objective measurement of platelet response, these
results highlight the utility of looking at platelet counts over
time for establishing clinical benefit. Twelve patients with
romiplostim treatment for >1 year in the extension study
had continuous responses ranging from 61 to 174 weeks.
Thus, platelet responses appear to be maintained with romi-
plostim in the vast majority of patients who respond accord-
ing to the IWG 2006 criteria. Grade ≥3 bleeding events
occurred in 16% of all 60 patients in this analysis and in
15% of the 34 patients with a response, with their incidence
decreasing over the course of the study.
The primary reason for drug discontinuation was the
DMC’s safety concern for the potential risk for disease pro-
gression to AML, and that transient increases in blast cells
might put patients at risk of diagnosis of and treatment for
AML. In this study, the rate of progression to AML was low.
During the extension study phase, only two patients had
transient appearance of peripheral blasts, which disappeared
after discontinuation of treatment. One patient had progres-
sion of MDS during the treatment phase of this study with-
out further progression to AML, and two patients progressed
to AML, for an annualised event rate of progression to AML
of 2% (95% CI; 02%, 7%).
Information on patients from the parent studies who pro-
gressed to AML (3 patients in the open-label dose-finding
study [N = 72] (Kantarjian et al, 2010; Sekeres et al, 2011)
and 12 patients in the double-blind study [N = 250]
(Giagounidis et al, 2014) is summarised in Table SIV. The
annualised rate of progression to AML in the double-blind
parent study (N = 250) was 80% (95% CI; 39%, 148%) for
patients receiving romiplostim (n = 10) and 32% (95% CI;
04%, 116%) for those receiving placebo (n = 2) (Giagouni-
dis et al, 2014). In the parent studies, 17 patients (101%)
receiving romiplostim and 7 patients (85%) receiving pla-
cebo met the criteria for worsening MDS (Giagounidis et al,
2014). Among the 25 patients with maximum peripheral
blast counts >10%, 12 patients had decreases to <10% with-
out treatment, two had decreases with treatment, two had
sustained increases and 9 patients did not have end-of-study
peripheral blood blast assessments, so their status is not
known (Giagounidis et al, 2014). Among three placebo recip-
ients with elevated peripheral blast counts, two had deceases
without treatment and one did not have an end-of-study
peripheral blood blast assessment (Giagounidis et al, 2014).
Four patients in the open-label dose-finding study had tran-
sient increases in blast cells ≥20% that subsequently fell to
below 20% (Sekeres et al, 2011).
There are a number of study limitations to consider.
Importantly, 25 of the 34 patients with a platelet response
discontinued treatment because of regulatory agency and/or
DMC recommendation, thereby limiting the assessment of
more prolonged romiplostim treatment. Because of differing
times of enrolment, approximately one-third of patients with
a response received romiplostim for <6 months; however, 15
of 34 patients with a response received romiplostim for
>12 months, including 10 patients with treatment
>156 weeks (3 years), helping to inform safety and efficacy
over multiple years of treatment. In addition, this extension
trial enrolled only patients who had not progressed to AML
and most had received romiplostim in the parent study,
which introduces potential selection bias. Patients with IPSS
low- to intermediate 1-risk MDS have a lower risk of AML
progression than patients with intermediate-2 or high-risk
MDS; the incidence of progression to AML (median follow-
up, 22 months) has been reported to be 13%, 22%, 46%,
and 65% in patients with low-risk, intermediate 1-risk,
intermediate 2-risk and high-risk MDS, respectively (Shukron
et al, 2012). The median romiplostim treatment exposure in
this study, combining parent and extension studies, was
approximately 15 years (up to 5 years). Therefore, the
recruitment of patients at low risk for AML progression,
combined with a relatively short duration of follow-up, may
have underestimated the risk of progression to secondary
AML compared with a more general MDS population.
In conclusion, platelet counts increased and bleeding
events decreased in patients with low- or intermediate 1-risk
MDS and thrombocytopenia treated long term with romi-
plostim monotherapy. Most patients with HI-P maintained
platelet responses while receiving romiplostim. The overall
safety and efficacy profiles were similar to those seen in other
romiplostim studies; no new safety signals were identified
and the rate of progression to AML was low.
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